Visual Ocuity Eye Drops were designed to support healthy eye function*.  The lens of the eye, unlike most body tissues, does not experience a turnover of cells. The eye cells we are born with are the eye cells we have our whole lives.

Many causes,  including smoke, dust, ultraviolet rays, excessive sugars, drug use, inadequate nutrient levels, and poor blood flow can lead to conditions such as cataracts, glaucoma, retinol/macular degeneration, corneal disorders, ocular inflammation, and complications of diabetes mellitus.

  • Importantly, VISUAL OCUITY contains the antioxidant N-Acetyl-Carnosine (NAC), a time-release form of the naturally occurring dipeptide L-Carnosine – a powerful antioxidant. This form of L-Carnosine protects and support against damage*.
  • In both human and animal studies, NAC has shown remarkable effects in protecting and healing the eyes.   Babizhayev, one of the leading researchers of NAC states “The NAC anti-cataract drops have been carefully tested. We have processed the treatment of age-related cataracts in canines and experimental models of cataracts in rabbits. The most striking results have been obtained using a 1% NAC instillation in canines. The cortical appearance of cataract reversal starts from the periphery and then the lens becomes more transparent. This is then accompanied by the improved visual behavior of the animal.”

Dr. Babizhayev is quoted as follows: “We developed sensitive measurements for lens opacities in humans. These were original techniques of glare tests; they are very sensitive to even tiny changes of the lens opacities and we also tested the macular function. One group of patients were the control reference group, they demonstrated the variability in densitometric readings of lens clouding and they had negative advance in glare sensitivity at 6 months, and a gradual deterioration of visual acuity and gross transmissivity of lenses at 24 months. However, when compared with baseline examination at 6 months, 41.5% of the eyes treated with NAC eye drops presented a significant improvement in visual acuity of 7-100% and 88.9% of the eyes ranged a 27-100% improvement in glare sensitivity.”

STATE OF THE ART  VISUAL OCUITY contains lubricants glycerin (1%) and hydroxypropylmethylcellulose 0.15%). VISUAL OCUITY  also contains: boric acid, citric acid, n-acetyl carnosine, potassium bicarbonate, purified benzyl alcohol, and sterile water.

Each box of Visual Ocuity contains 2 squeeze tube vials with 5 ml of drops per vial.

Directions for Use: Apply 1 or 2 drops in the affected eye(s) as needed.

*This statement has not been evaluated by the Food & Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.